Palbociclib plus letrozole clinical outcomes PALOMA-2

In PALOMA-2, palbociclib plus letrozole significantly improved progression-free survival by 13 months compared to letrozole alone (27.6 vs 14.5 months) with manageable hematologic toxicity and maintained quality of life, but did not demonstrate a significant overall survival benefit after 90 months of follow-up.

Abstract

The PALOMA-2 trial demonstrated that palbociclib plus letrozole significantly improved progression-free survival compared to placebo plus letrozole in postmenopausal women with ER+/HER2- advanced breast cancer. Median PFS was 27.6 months versus 14.5 months (HR 0.56, P<0.0001), with consistent benefit observed across all patient subgroups including Asian patients (25.7 vs 13.9 months, HR 0.49, P=0.007) and those with low disease burden. Notably, PFS improvement occurred regardless of objective response status, with non-responders experiencing median PFS of 10.9 versus 5.6 months (HR 0.72, P=0.016). The treatment delayed time to subsequent chemotherapy by approximately 10 months (40.4 vs 29.9 months). However, after 90.1 months of follow-up, median overall survival was 53.9 versus 51.2 months (HR 0.96, P=0.34), showing no significant improvement.

The primary toxicity was hematologic, with grade 3-4 neutropenia occurring in 66.4% of patients (vs 1.4% with placebo), increasing to 89.2% in Asian populations. Despite this, febrile neutropenia remained rare (1.8-2.0%), and treatment discontinuation rates were low (9.7-12.2% vs 5.9%). Quality of life was maintained with no significant differences in FACT-Breast Total or EQ-5D scores between treatment arms, and pain scores significantly improved with palbociclib plus letrozole (P=0.0183). Neutropenia did not negatively impact quality of life measures.

Methods

We analyzed 10 sources from an initial pool of 200, using 6 screening criteria. Each paper was reviewed for 8 key aspects that mattered most to the research question.

Screening Criteria

• PALOMA-2 Trial Relevance: Does this study report on the PALOMA-2 trial (NCT01740427) or its secondary/post-hoc analyses?
• Patient Population: Does this study include patients with hormone receptor-positive, HER2-negative advanced breast cancer?
• Clinical Outcomes: Does this study report clinical efficacy outcomes (progression-free survival, overall survival, objective response rate, clinical benefit rate), safety and tolerability outcomes, quality of life analyses, or is it a systematic review/meta-analysis that includes PALOMA-2 data?
• Intervention Specificity: Does this study focus on palbociclib plus letrozole combination therapy (rather than palbociclib with other endocrine partners or palbociclib monotherapy)?
• Disease Population Specificity: Does this study focus on the appropriate breast cancer population (not exclusively triple-negative, HER2-positive, or early-stage disease)?
• Study Design Appropriateness: Is this study a clinical study in humans (not preclinical, in vitro, animal studies, case reports, or case series)?

Results

Characteristics of Included Studies

The included publications comprised analyses from the PALOMA-2 trial, a phase 3 randomized controlled trial that enrolled 666 postmenopausal women with ER+/HER2- advanced breast cancer. Patients were randomized 2:1 to palbociclib plus letrozole (n=444) or placebo plus letrozole (n=222). Key eligibility criteria included no prior systemic therapy for advanced disease and performance status 0-2.

Treatment

• Palbociclib dosing: 125 mg/day for 3 weeks on/1 week off plus letrozole 2.5 mg/day continuously, or matching placebo plus letrozole. Median treatment duration was approximately 22-30 months for palbociclib plus letrozole depending on objective response status.

Efficacy Outcomes

Progression-Free Survival

• Median PFS was significantly improved for palbociclib plus letrozole across all analyses compared to placebo plus letrozole.
• Primary analysis: 24.8 months vs 14.5 months (HR 0.58, P<0.001)
• Extended follow-up: 27.6 months vs 14.5 months (HR 0.56, P<0.0001)

Safety Outcomes

Hematologic Toxicities

• Neutropenia was the most common adverse event in patients receiving palbociclib plus letrozole (66.4% grade 3-4) compared to 1.4% in the placebo arm.
• Serious adverse events were more common in the palbociclib arm (23.6% vs 15.3%). Infections were the most frequently reported serious adverse events.

Patient-Reported Outcomes and Quality of Life

• Patient-reported outcomes indicated maintenance of health-related quality of life, with pain scores improving significantly with palbociclib plus letrozole compared to letrozole alone (P=0.0183). Neutropenia did not significantly impact quality of life measures.

Subgroup Analyses

All subgroups analyzed demonstrated benefit from the addition of palbociclib to letrozole, with specific findings across various patient demographics and disease characteristics.

Clinical Implications

The authors concluded that palbociclib plus letrozole provides significant clinical benefit in terms of PFS even in patients who do not achieve an objective response, suggesting its role as a viable first-line therapy for patients with HR+/HER2- advanced breast cancer.